Understanding Type 2 Inflammation
Join us for an exciting continuing education series as we explore how T2 inflammation underpins the complex pathophysiology of chronic inflammation in asthma, atopic dermatitis, COPD, and eosinophilic esophagitis (EoE) as well as comorbid disease.
- Live and on-demand CE activities certified for nurses, pharmacists, and physicians
- Designed for managed care professionals
- Learn about T2 inflammation pathways, the safety and efficacy of treatments used to manage patients, and how to effectively employ care management strategies based on current evidence that can improve access and quality of care for patients
- The series builds from each topic so it is important to sign up for the entire series
Podcasts
Track 1: Spotlight on EoE
Track 2: Best Practices in EoE Management
Now available at: www.impactedu.net/type2-inflammation-eoe-management
PayerTalkCE™ Presents: Understanding Type 2 Inflammation
Track 1 - Spotlight on Eosinophilic Esophagitis
Track 2 - Best Practices in EoE Management
- Release Date: November 30, 2024
- Expiration Date: May 31, 2026
- Estimated Time to Complete Activity: 0.75 hour per track
- Compatible with all modern browsers and mobile devices
 |
||||||||||||||
Expert Faculty |
||||||||||||||
|
||||||||||||||
Target Audience
The activities are designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Managed care professionals report having limited knowledge of EoE pathology, noting that misdiagnosis and underdiagnosis are common issues preventing patients from receiving timely and accurate treatment. In conditions like EoE, where understanding of the disease mechanisms is still developing, managed care payers may not prioritize these conditions highly. Therefore, managed care professionals must understand the disease, treatment protocols, and evidence-based practices to identify effective, safe, and cost-efficient medications for their formularies. A deeper understanding of T2 inflammation will enable these professionals to collaborate more effectively with specialist physicians, ensuring that care plans are comprehensive, aligned with clinical guidelines, and free from unnecessary administrative barriers to appropriate care.
Educational Objectives
After completing this activity, the participant should be better able to:
Track 1:
- Describe how T2 inflammation plays a central role in EoE pathophysiology
- Summarize safety and efficacy of treatments for patients with EoE
Track 2:
- Describe how T2 inflammation plays a central role in EoE pathophysiology
- Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines
Accreditation Information
 |
Joint Accreditation Statement |
Physician Continuing Medical Education
PACE designates these enduring activities for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
PACE designates these continuing education activities for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-24-285-H01-P - 0.75 contact hour.
This activity is certified as Knowledge-based CPE.
Track 2: JA4008073-9999-24-286-H01-P - 0.75 contact hour.
This activity is certified as Knowledge-based CPE.
For Pharmacists: After successfully completing the online evaluation you must click Claim Credit and select "CPE" as the credit type to submit your credit to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Continuing Nursing Education
The maximum number of hours awarded for these Continuing Nursing Education activities is 0.75 contact hour.
Track 1: Spotlight on Eosinophilic Esophagitis – 0.75 contact hour
Track 2: Best Practices in EoE Management – 0.75 contact hour
DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Dana McCormick, RPh, FAMCP | Nothing to report. |
| Evan S. Dellon, MD, MPH | Researcher - Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda Consultant/Advisor/Speaker - Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio Educational Grant - Allakos, Holoclara, Invea |
| Drake Reiter, PharmD | Nothing to report. |
The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
The educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Infographics
Track 1: Spotlight on EoE
Track 2: Best Practices in EoE Management
Now available at: www.impactedu.net/type2-inflammation-eoe-infographic
PayerTalkCE™ Presents: Understanding Type 2 Inflammation
Track 1 - Spotlight on Eosinophilic Esophagitis Infographic
Track 2 - Best Practices in EoE Management Infographic
- Release Date: November 30, 2024
- Expiration Date: May 31, 2026
- Estimated Time to Complete Activity: 0.5 hour per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty |
||||||||||||||
|
||||||||||||||
Target Audience
The infographics are designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Managed care professionals report having limited knowledge of EoE pathology, noting that misdiagnosis and underdiagnosis are common issues preventing patients from receiving timely and accurate treatment. In conditions like EoE, where understanding of the disease mechanisms is still developing, managed care payers may not prioritize these conditions highly. Therefore, managed care professionals must understand the disease, treatment protocols, and evidence-based practices to identify effective, safe, and cost-efficient medications for their formularies. A deeper understanding of T2 inflammation will enable these professionals to collaborate more effectively with specialist physicians, ensuring that care plans are comprehensive, aligned with clinical guidelines, and free from unnecessary administrative barriers to appropriate care.
Educational Objectives
After completing this activity, the participant should be better able to:
Track 1:
- Describe how T2 inflammation plays a central role in EoE pathophysiology
Track 2:
- Describe how T2 inflammation plays a central role in EoE pathophysiology
- Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
PACE designates these enduring activities for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
PACE designates these continuing education activities for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-24-285-H01-P - 0.5 contact hour.
This activity is certified as Knowledge-based CPE.
Track 2: xxxxx - 0.5 contact hour.
This activity is certified as Knowledge-based CPE.
CPE Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hours.
Track 1: Spotlight on Eosinophilic Esophagitis – 0.5 contact hour
Track 2: Best Practices in EoE Management – 0.5 contact hour
DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Dana McCormick, RPh, FAMCP | Nothing to report. |
| Evan S. Dellon, MD, MPH | Researcher - Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda Consultant/Advisor/Speaker - Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio Educational Grant - Allakos, Holoclara, Invea |
| Drake Reiter, PharmD | Nothing to report. |
DISCLOSURE OF UNLABELED USE
The educational activities may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activities are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Expert Faculty Presenters:
Dana McCormick, RPh, FAMCP
Senior Director, Pharmacy Advisor Services
Optum Insights
Related Activity
Evan S. Dellon, MD, MPH
Professor of Medicine and Adjunct Professor of Epidemiology
University of North Carolina School of Medicine
Related Activity
Drake Reiter, PharmD
Director, Pharmacy Operations
Priority Health
Related Activity
Podcast
Track 1: Spotlight on Atopic Dermatitis
Track 2: Best Practices in Atopic Dermatitis Management
Now available at: www.impactedu.net/type2-inflammation-atopic-dermatitis-management-ce/
PayerTalkCE® Presents: Understanding Type 2 Inflammation: Atopic Dermatitis
Track 1 - Spotlight on Atopic Dermatitis
Track 2 - Best Practices in Atopic Dermatitis Management
- Release Date: January 31, 2025
- Expiration Date: July 31, 2026
- Estimated Time to Complete Activity: 0.75 hours per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty |
||||||||||||||
|
||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Despite significant advances in understanding of the underlying etiology of AD, there remains a need to improve the overall management of AD to gain better control of the disease and reduce its clinical and humanistic burden. New systemic therapies that specifically target cytokines reveal the importance of major T2 cytokines IL-4 and IL-13 in AD pathophysiology. However, managed care professionals lack knowledge of how T2 inflammation impacts AD and the appropriate treatments to manage these patients. In addition, managed care professionals lack competence to effectively employ care management strategies based on current evidence that can improve treatment access and overall quality of care for patients with AD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe how T2 inflammation plays a central role in atopic dermatitis pathophysiology
- Summarize safety and efficacy of treatments for patients with atopic dermatitis
- Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
PACE designates each continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-25-013-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-014-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.75 contact hour.
Track 1: Spotlight on Atopic Dermatitis – 0.75 contact hour
Track 2: Best Practices in Atopic Dermatitis Management – 0.75 contact hour
DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Dana McCormick, RPh, FAMCP | Nothing to report. |
| Shawn G. Kwatra, MD | Nothing to report. |
| Drake Reiter, PharmD | Nothing to report. |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Infographic
Track 1: Spotlight on Atopic Dermatitis
Track 2: Best Practices in Atopic Dermatitis Management
Now available at: www.impactedu.net/type2-inflammation-atopic-dermatitis-infographic/
PayerTalkCE® Presents: Understanding T2 Inflammation: Atopic Dermatitis
Track 1 - Spotlight on Atopic Dermatitis Infographic
Track 2 - Best Practices in Atopic Dermatitis Management Infographic
- Release Date: January 31, 2025
- Expiration Date: July 31, 2026
- Estimated Time to Complete Activity: 0.5 hours per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty Presenters |
||||||||||||||
|
||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Despite significant advances in understanding of the underlying etiology of AD, there remains a need to improve the overall management of AD to gain better control of the disease and reduce its clinical and humanistic burden. New systemic therapies that specifically target cytokines reveal the importance of major T2 cytokines IL-4 and IL-13 in AD pathophysiology. However, managed care professionals lack knowledge of how T2 inflammation impacts AD and the appropriate treatments to manage these patients. In addition, managed care professionals lack competence to effectively employ care management strategies based on current evidence that can improve treatment access and overall quality of care for patients with AD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe how T2 inflammation plays a central role in atopic dermatitis pathophysiology
- Summarize safety and efficacy of treatments for patients with atopic dermatitis
- Assess payer care management initiatives and other opportunities to improve treatment access and overall quality of care based on current evidence from clinical trials and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
PACE designates each continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-25-017-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-018-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.
Track 1: Spotlight on Atopic Dermatitis Infographic – 0.5 contact hour
Track 2: Best Practices in Atopic Dermatitis Management Infographic – 0.5 contact hour
DISCLOSURE
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Dana McCormick, RPh, FAMCP | Nothing to report. |
| Shawn G. Kwatra, MD | Nothing to report. |
| Drake Reiter, PharmD | Nothing to report. |
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Expert Faculty Presenters:
Dana McCormick, RPh, FAMCP
Senior Director, Pharmacy Advisor Services
Optum Insights
Related Activity
Shawn G. Kwatra, MD, FAAD
Chair, Department of Dermatology and Chief of Service of Dermatology
University of Maryland Medical Center (UMMC)
Related Activity
Drake Reiter, PharmD
Director, Pharmacy Operations
Priority Health
Related Activity
Podcast
Track 1: Spotlight on Moderate-to-Severe Asthma
Track 2: Best Practices in Moderate-to-Severe Asthma Management
Now available at: www.impactedu.net/type2-inflammation-asthma-management-ce/
PayerTalkCE® Presents: Understanding Type 2 Inflammation: Moderate-to-Severe Asthma
Track 1 - Spotlight on Moderate-to-Severe Asthma
Track 2 - Best Practices in Moderate-to-Severe Asthma Management
- Release Date: March 1, 2025
- Expiration Date: August 31, 2026
- Estimated Time to Complete Activity: 0.75 hours per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty |
||||||||||||||
|
||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
T2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease. Managed care professionals require education regarding T2 inflammation pathways in asthma and comorbidities as well as the safety and efficacy of treatments used to manage patients with moderate-to-severe asthma. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with moderate-to-severe asthma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Explain how T2 inflammation plays a central role in asthma pathophysiology and common comorbidities
- Review safety and efficacy of pharmaceuticals targeting T2 inflammation in moderate-to-severe asthma
- Cite payer care management initiatives and other opportunities to improve patient access and quality of care based on current evidence from clinical trials, real-world experience, and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
PACE designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-25-069-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-070-H01-P- 0.75 contact hour. This activity is certified as Application-based CPE.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.
Track 1: Spotlight on Moderate-to=Severe Asthma – 0.75 contact hour
Track 2: Best Practices in Moderate-to=Severe Asthma Management – 0.75 contact hour
DISCLOSURE OF CONFLICTS OF INTEREST
Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Jeffrey D. Dunn, PharmD, MBA | Faculty for this activity, has no relevant financial relationships. |
| Michael Kobernick, MD, MS, MS-PopH, CPE | Faculty for this activity, has no relevant financial relationships. |
| Anju T. Peters, MD, MSCI, FAAAAI | Faculty for this activity, has the following relevant financial relationships:
|
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Infographic
Track 1: Spotlight on Moderate-to-Severe Asthma
Track 2: Best Practices in Moderate-to-Severe Asthma Management
Now available at: www.impactedu.net/type2-inflammation-asthma-infographic/
Understanding T2 Inflammation: Moderate-to-Severe Asthma
Track 1 - Spotlight on Moderate-to-Severe Asthma Infographic
Track 2 - Best Practices in Moderate-to-Severe Asthma Management Infographic
- Release Date: March 1, 2025
- Expiration Date: August 31, 2026
- Estimated Time to Complete Activity: 0.5 hours per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty |
||||||||||||||
|
||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
T2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease. Managed care professionals require education regarding T2 inflammation pathways in asthma and comorbidities as well as the safety and efficacy of treatments used to manage patients with moderate-to-severe asthma. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with moderate-to-severe asthma.
Educational Objectives
After completing this activity, the participant should be better able to:
- Explain how T2 inflammation plays a central role in asthma pathophysiology and common comorbidities
- Review safety and efficacy of pharmaceuticals targeting T2 inflammation in moderate-to-severe asthma
- Cite payer care management initiatives and other opportunities to improve patient access and quality of care based on current evidence from clinical trials, real-world experience, and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
PACE designates each enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
PACE designates each continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-25-084-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-085-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.
Track 1: Spotlight on Moderate-to-Severe Asthma – 0.5 contact hour
Track 2: Best Practices in Moderate-to-Severe Asthma Management – 0.5 contact hour
DISCLOSURE OF CONFLICTS OF INTEREST
Disclosures
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Jeffrey D. Dunn, PharmD, MBA | Faculty for this activity, has no relevant financial relationships. |
| Michael Kobernick, MD, MS, MS-PopH, CPE | Faculty for this activity, has no relevant financial relationships. |
| Anju T. Peters, MD, MSCI, FAAAAI | Faculty for this activity, has the following relevant financial relationships:
|
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Expert Faculty Presenters:
Jeffrey D. Dunn, PharmD, MBA
President and CEO
Cooperative Benefits Group (CBG)
Related Activity
Michael Kobernick, MD, MS, MS-PopH, CPE
Senior Medical Director – Health Plan Business
Blue Cross Blue Shield of Michigan
Lecturer
Jefferson College of Population Health
Related Activity
Anju T. Peters, MD, MSCI, FAAAAI
Professor of Medicine and Director of Clinical Research
Division of Allergy/Immunology and Otolaryngology
Northwestern University Feinberg School of Medicine
Related Activity
Podcast
Track 1: Spotlight on COPD
Track 2: Best Practices in COPD Management
Now available at: www.impactedu.net/type2-inflammation-copd-management/
PayerTalkCE® Present: Understanding T2 Inflammation: Spotlight on COPD
Track 1 - Understanding T2 Inflammation: Spotlight on COPD
Track 2 - Understanding T2 Inflammation: Best Practices in COPD Management
- Release Date: May 1, 2025
- Expiration Date: November 30, 2026
- Estimated Time to Complete Activity: 0.75 hours per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty Presenters |
||||||||||||||
|
||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Type 2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in COPD, as well as the presence of comorbid disease. Managed care professionals will benefit from education regarding T2 inflammation pathways in COPD and comorbidities as well as the safety and efficacy of treatments used to manage patients with COPD. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with COPD.
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe how T2 inflammation plays a central role in COPD pathophysiology and common comorbidities
- Summarize safety and efficacy for biologics used to manage patients with COPD
- Assess payer care management initiatives and other opportunities to improve the quality of care based on current evidence from clinical trials and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.75 AMA PRA Category 1 Credit™
Track 2: 0.75 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
Partners designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-25-139-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Track 2: JA4008073-9999-25-140-H01-P - 0.75 contact hour. This activity is certified as Application-based CPE.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.
Track 1: Spotlight on COPD – 0.75 contact hour
Track 2: Best Practices in COPD Management – 0.75 contact hour
DISCLOSURE OF CONFLICTS OF INTEREST
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
| Jeffrey D. Dunn, PharmD, MBA, faculty for this activity, has no relevant financial relationships. |
MeiLan Han, MD, MS: faculty for this activity, has the following relevant financial relationships:
|
Matthew Harman, PharmD, MPH, faculty for this activity, has the following relevant financial relationships:
|
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Infographic
Track 1: Spotlight on COPD
Track 2: Best Practices in COPD Management
Now available at: www.impactedu.net/type2-inflammation-copd-infographic/
PayerTalkCE® Presents: Understanding T2 Inflammation: COPD
Track 1 - Understanding T2 Inflammation: Spotlight on COPD Infographic
Track 2 - Understanding T2 Inflammation: Best Practices in COPD Management Infographic
- Release Date: May 1, 2025
- Expiration Date: November 30, 2026
- Estimated Time to Complete Activity: 0.5 hours per track
- Compatible with all modern browsers and mobile devices
|
||||||||||||||
Expert Faculty Presenters |
||||||||||||||
|
||||||||||||||
Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.
Statement of Need/Program Overview
Type 2 inflammation, involving both the innate and adaptive immune systems, underpins the complex pathophysiology of chronic inflammation in COPD, as well as the presence of comorbid disease. Managed care professionals will benefit from education regarding T2 inflammation pathways in COPD and comorbidities as well as the safety and efficacy of treatments used to manage patients with COPD. This activity will explore care management strategies based on current evidence that can improve access and quality of care for patients with COPD.
Educational Objectives
After completing this activity, the participant should be better able to:
Track 1:
- Describe how T2 inflammation plays a central role in COPD pathophysiology and common comorbidities
Track 2:
- Describe how T2 inflammation plays a central role in COPD pathophysiology and common comorbidities
- Assess payer care management initiatives and other opportunities to improve the quality of care based on current evidence from clinical trials and treatment guidelines
Accreditation Information
|
Joint Accreditation Statement |
Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Track 1: 0.5 AMA PRA Category 1 Credit™
Track 2: 0.5 AMA PRA Category 1 Credit™
Continuing Pharmacy Education
Partners designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
Track 1: JA4008073-9999-25-139-H01-P- 0.5 contact hour. This activity is certified as Application-based CPE.
Track 2: - JA4008073-9999-25-140-H01-P- 0.5 contact hour. This activity is certified as Application-based CPE.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.
Track 1: Spotlight on COPD – 0.5 contact hour
Track 2: Best Practices in COPD Management – 0.5 contact hour
DISCLOSURE OF CONFLICTS OF INTEREST
Disclosures
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
| Jeffrey D. Dunn, PharmD, MBA, faculty for this activity, has no relevant financial relationships. |
MeiLan Han, MD, MS: faculty for this activity, has the following relevant financial relationships:
|
Matthew Harman, PharmD, MPH, faculty for this activity, has the following relevant financial relationships:
|
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION
There is no fee for this educational activity.
Expert Faculty Presenters:
Jeffrey D. Dunn, PharmD, MBA
President and CEO
Cooperative Benefits Group (CBG)
Related Activity
MeiLan Han, MD, MS
Professor of Medicine
Chief of the Division of Pulmonary and Critical Care
University Of Michigan Health
Related Activity
Matthew Harman, PharmD, MPH
VP of Clinical Solutions
Employers Health
Related Activity
Provided by:
Supported by independent educational grants from Regeneron Pharmaceuticals, Inc. and Sanofi.